Denali Therapeutics Inc. - Common Stock (DNLI)

Historical Holders from Q4 2017 to Q1 2025

Symbol
DNLI on Nasdaq
CUSIP
24823R105
Type / Class
Equity / Common Stock
Shares outstanding
146M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
128M
Holdings value
$2.61B
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
220
Number of buys
111
Number of sells
-92
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Denali Therapeutics Inc. - Common Stock (DNLI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $148M 10.5M BlackRock, Inc. Mar 31, 2025
Capital Research Global Investors 3.8% $87.4M 5.48M Capital Research Global Investors Dec 31, 2024
BAILLIE GIFFORD & CO 7.2% $43.7M 2.74M BAILLIE GIFFORD & CO Dec 31, 2024

Institutional Holders of Denali Therapeutics Inc. - Common Stock (DNLI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 665K $9.04M +$161K $13.60 19
2024 Q4 128M $2.61B +$19.4M $20.38 220
2024 Q3 126M $3.68B +$76.2M $29.13 215
2024 Q2 120M $2.78B +$111M $23.22 202
2024 Q1 121M $2.49B +$125M $20.52 208
2023 Q4 111M $2.38B +$35.3M $21.46 205
2023 Q3 108M $2.22B +$10.7M $20.63 191
2023 Q2 107M $3.15B -$754K $29.51 195
2023 Q1 108M $2.48B +$45.5M $23.04 195
2022 Q4 106M $2.94B +$355M $27.81 190
2022 Q3 91.6M $2.81B -$38.2M $30.69 187
2022 Q2 92.2M $2.71B +$189M $29.43 172
2022 Q1 86.5M $2.78B +$41.7M $32.17 172
2021 Q4 85.2M $3.8B +$12.2M $44.60 201
2021 Q3 84.8M $4.28B +$170M $50.45 206
2021 Q2 77.8M $6.1B +$34M $78.44 205
2021 Q1 77.7M $4.44B +$73.6M $57.10 211
2020 Q4 66M $5.53B +$204M $83.76 197
2020 Q3 82.5M $2.96B +$14.8M $35.83 165
2020 Q2 82.6M $2B +$63.5M $24.18 139
2020 Q1 80.1M $1.4B +$148M $17.51 123
2019 Q4 70.7M $1.23B -$9.09M $17.42 106
2019 Q3 71.2M $1.09B -$4.83M $15.32 110
2019 Q2 71.3M $1.48B +$62.5M $20.76 111
2019 Q1 68.9M $1.6B +$23.5M $23.22 111
2018 Q4 68M $1.41B -$870K $20.66 86
2018 Q3 67M $1.46B +$109M $21.74 76
2018 Q2 62.2M $949M +$18.8M $15.25 66
2018 Q1 60.8M $1.2B +$60.2M $19.69 56
2017 Q4 58.1M $909M +$768M $15.64 44